

AD _____

Award Number: DAMD17-98-1-8165

TITLE: Sequence Motifs Specifying Homing and Metastasis to Bone

PRINCIPAL INVESTIGATOR: Jose Luis Millan, Ph.D.

CONTRACTING ORGANIZATION: The Burnham
La Jolla, California 92037

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020814 167

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED	
	July 2001	Annual (1 Jul 00 - 30 Jun 01)	
4. TITLE AND SUBTITLE Sequence Motifs Specifying Homing and Metastasis to Bone			5. FUNDING NUMBERS DAMD17-98-1-8165
6. AUTHOR(S) Jose Luis Millan, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Burnham La Jolla, California 92037 E-Mail: millan@burnham.org			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES Report contains color			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Our aim is to identify molecules that mediate the specific homing of metastatic tumor cells to bone. Our approach involves the use of random peptide libraries expressed on the surface of filamentous phage as well as novel expression cloning strategies using immortalized bone marrow stromal and endothelial cells to detect the binding of COS-1 cells transfected with cDNAs from the bone metastatic MDA-MB-231 breast cancer cell line. Using both these approaches we have successfully identified 10 peptides by <i>in vivo</i> phage display and two novel cDNAs by expression cloning and work continues on the characterization of these molecules. This past year we also developed a new <i>in vivo</i> targeting strategy based on injecting transfected COS-1 cells into mice and recovering the transfected plasmids from those cells that home to the bone marrow. With this new strategy we have isolate 15 new promising clones. These experimental approaches will lead to the discovery of molecules involved in metastasis which remains today one of fundamental unresolved problems in tumor biology. Furthermore, identification of bone specific homing sequences could enable us to design vectors to be used in gene therapy of genetic diseases effecting bone and/or to block bone metastasis.			
14. SUBJECT TERMS Random peptide libraries, bone metastasis, endothelial cells, stromal cells, ligand/receptor cloning, <i>in vivo</i> targeting			15. NUMBER OF PAGES 13
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


11/16/01

PI - Signature Date

4. Table of Contents

	Page Numbers
Cover	1
SF 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	6
Key Research Accomplishments	11
Reportable Outcomes	12
Conclusions	12
References	12
Appendices	n/a

5. INTRODUCTION

More than 70 % of breast cancer patients show bone metastasis at the time of autopsy. Bone metastasis is a devastating symptom, which can cause bone fractures, severe pain, hypercalcemia and/or neurological paralysis. Despite its clinical importance, the mechanisms that cause bone preferential metastasis are not well understood. Currently no efficient methods to prevent or treat bone metastasis are available. The establishment of metastasis requires multiple steps. First cancer cells within the epithelium of the primary organ must be released. After reaching the blood vessels, the cells rupture the basement membrane and are released into the circulation. Floating cancer cells initially adhere to endothelial cells of the secondary organ and then invade the stroma. If they successfully proliferate within the secondary organ, metastasis is established (Hynes and Lander, 1992). We have focused on the initial adhesion of breast cancer cells in the secondary organ, bone marrow. We hypothesize that breast cancer cells released into the circulation adhere to the stromal cells and/or endothelial cells in the bone marrow through specific binding(s). Although little information is currently available about the molecules involved in this step of breast cancer, in other cancers receptor/ligand-like specific interactions mediating metastasis have been characterized. For example, VLA-4 ($\alpha_4\beta_1$) integrin on skin melanoma binds to VCAM-1 (vascular cell adhesion molecules 1) expressed on activated endothelial cells, and Sialyl Lewis X on colon cancer recognizes E-selectin expressed on hepatic endothelium (Zetter, 1993). Prostate cancers also show a high incidence of bone metastasis. Haq et al. showed that a rat prostate cancer cell line contained a population preferentially bound to bone marrow-derived endothelial cells (Haq et al., 1992). Tumors of prostate cancer patients who developed bone metastasis and those of the patients who developed lymph node metastasis presented different lectin binding patterns indicating the existence of molecules that help to determine the preference for the secondary organ (McMahon et al., 1994). Generally, it is believed that floating cancer cells bind first to the endothelial cells of the secondary organ; however, we decided to focus on both the bone marrow stromal cells and endothelial cells for our studies. Bone marrow has a unique structure called the "bone marrow sinus", which has an intermittent basement membrane allowing matured hematopoietic cells to be released into circulation (Apaja-Sarkkinen et al., 1986). This observation likely indicates that cells in circulation can easily enter the bone marrow cavity. Therefore, endothelial cells may not be the only cells that floating breast cancer cells first interact with. Bone marrow stromal cells function in the maturation and sorting of hematopoietic cells. It has been suggested that VCAM-1 expressed in certain bone marrow stromal cells mediates adhesion to hematopoietic cells (Jacobson et al., 1996). Isoforms of CD44, which is one of the cell adhesion receptors expressed in bone marrow stromal cells, may be involved in metastasis (Lesley et al., 1993). VLA-4, a receptor of VCAM-1, expressed in myeloma cells binds to VCAM-1 on the bone marrow stromal cells suggesting that VLA-4 /VCAM-1 interaction facilitates homing of myeloma to bone (Michigami, et al., 2000).

We are using complementary approaches to try to uncover molecules that home specifically to bone. One is a novel approach developed at our institute that makes use of random peptide libraries expressed on the surface of filamentous phage in order to identify peptides that may confer preferential homing properties. A second approach is a more classical panning strategy, whereby a metastatic breast cancer cell line is used to generate a cDNA library that is then expressed in a mammalian expression system. To do this, we have generated a number of immortalized bone marrow stromal and endothelial cell lines and developed a novel binding assay to identify the binding of transfectants onto the bone marrow cell lines. Still a third approach has been developed this past year, which involves the *in vivo* targeting of transfected COS-1 cells followed by recovery of the plasmids from those

transfectants that home specifically to the bone marrow. All three of these experimental approaches may lead to uncovering the basic mechanisms of bone metastasis by cancer cells which remain today one of the fundamental unresolved problems in tumor biology. In a more general application, identification of bone-specific homing sequences would enable the design of vectors to be used in gene therapy of genetic diseases affecting bone.

6. BODY

The approved tasks for this project include:

- 1) To generate and screen random peptide libraries *in vivo* to identify sequence motifs homing specifically to bone.
- 2) To ascertain if the peptide sequences exist in the context of full length cDNA molecules present on metastatic breast cancer cells
- 3) To identify and clone the receptors on the surface of bone marrow endothelial cells that are recognized by the homing peptides.

During this third year of support we have continued to obtain information on the previously identified clones while we have also optimized an alternative *in vivo* targeting strategy and uncovered new candidate sequences. I will now summarize our major advances :

Results from expression cloning experiments using a bone marrow stromal cell line:




Fig. 1 Bone marrow cells were isolated from the Immortomouse and clone BMS6 and BME5 were chosen due to their ability to capture MDA-MB-231 cells. cDNA expression library of bone metastatic breast cancer MDA-MB-231 was expressed in COS-1 cells. Cytoplasmic DNA from the COS-1 cells bound to BMS6 was recovered and this cycle was repeated.

We developed an expression cloning strategy designed to identify molecules that bind to bone marrow cells (Fig. 1). The establishment of this cloning system required three steps. (I) First, we immortalized bone marrow stromal cells and endothelial cells. These cells are considered the target cells to which breast cancer cells bind. (II) Secondly, we constructed a cDNA expression library of the human breast cancer cell line MDA-MB-231 (231), (III) Finally, we expressed the library, incubated those cells with our immortalized bone marrow stromal cells, and recovered cDNA clones from the COS-1 cells that bound to the stromal cells.

Although the breast cancer cell line 231 was established from pleural fluid from a breast cancer patient (Cailleau et al., 1974), it is believed to maintain "bone metastatic characteristics", since it can colonize the bone marrow of nude mice if injected through the left cardiac ventricle, while the control breast cancer cell line MCF7 can not (Yoneda et al., 1994). We previously observed that 231 cells contained a subpopulation that bound to primary cultures of mouse bone marrow cells. Firstly, we established cell lines isolated from the bone marrow of the Immortomouse (Charles River Laboratories, Wilmington, MA), a transgenic mouse ubiquitously expressing SV40 large T antigen. Cells isolated from the Immortomouse proliferate under permissive conditions i.e., in the presence of 100 units/ml IFN- γ in the media at 33°C (Jat et al., 1991). After single-cell cloning of the primary culture, seven stromal cell clones and nine endothelial cell clones were obtained, and their morphology and the expression patterns of marker proteins were examined. Endothelial growth factor supplement (Sigma, St. Louis, MO) was used for the establishment of endothelial cell clones (Haq et al., 1992). We have chosen one stromal cell line (BMS6) and one endothelial cell line (BME5) because of their superior binding to 231 cells. BMS6 cells express stromal cell markers, such as alkaline phosphatase and CD44, and BME5 cells express endothelial cell markers, alkaline phosphatase, von Willebrand factor and VCAM-1. Fig. 2 shows alkaline phosphatase activity in BMS6 and BME5. Next, we constructed an expression library of the 231 cell line using an expression vector pCMV-Script (Stratagene, La Jolla, CA). This plasmid library has an average insert size of 1.3 kb and a size of is 4.0×10^5 primary colony forming units.





Fig. 2 BMS6 and BME5 stained for alkaline phosphatase (red). Nucleus were stained with methyl green.



The process of the expression cloning is illustrated in Fig. 3. Forty μ g of plasmid DNAs of the library were transfected into COS-1 cells by electroporation, and 60 hours later, the cells were harvested with 1% collagenase A (Roche, Indianapolis, IN) solution containing 0.005% trypsin inhibitor (Sigma, St. Louis, MO) and 5mM CaCl₂. BMS6 cells were fixed with ethanol and washed with serum free medium. The COS-1 cells suspended in culture medium containing 0.11 % EDTA were incubated on top of the BMS6 cells under mild shaking for 30 min. After eight times of washing with 0.02 % EDTA-PBS, amplified DNA was recovered from the cytoplasm of bound COS-1 cells and used for transformation of XL-10 Gold Ultracompetent Cells (Stratagene, La Jolla, CA).

A total of 140 clones were collected after the first cycle, cultured individually, and divided into ten groups (A to N). Fifty μ g of DNA from each group were transfected into COS-1 cells again, and amplified plasmids from the bound COS-1 cells were recovered. Ten cDNA clones from each group

were sequenced, and the sequences were compared to the databases. Twenty-two clones were chosen because they appeared more than twice, had large insert (more than 1 kb), were unknown sequences, or were membrane proteins.

Each cDNA clone was individually transfected into COS-1 cells, and the cells were processed as described in the previous step. After eight times of washing with 0.02 % EDTA-PBS, the samples were stained with trypan blue. Live bound COS-1 cells appeared as round, shining cells, while the target fixed cells were stained with trypan blue as shown in Fig.4. Clones A3 and A5 showed significant binding, and clone H7 was considered as negative.





Fig. 4 Binding assay. COS-1 cells transfected with clone A3, A5, and H1 incubated with fixed BMS6 cells. MDA-MB-231 cells were positive control. Live bound cells appear in white round shape.



Clone A3: Clone A3 is a 1.1 kb fragment containing entire coding sequence of CD59, which is known as a GPI anchored membrane protein. CD59 binds to complement 8 and 9. It is suggested that CD59 expressed on the surface of cancer cells protects them from complement attack (Chen et al., 2000). However, no function for CD59 has been proposed in cell-cell adhesion. Northern blot hybridization with a probe of clone A3 to human cancer cell lines is shown in Fig. 5. A3 is highly expressed in 231 and a prostate cancer cell line PC3 established from bone metastasis. The expression of A3 is lower in MDA-MB-361 cells, which are a breast cancer line isolated from brain metastasis, and breast cancer cell line MCF7, which does not colonize the bone marrow in nude mice (Yoneda et al., 1994). The remaining cell lines analyzed were non-breast cancers but isolated from bone metastasis. The multiple bands seen in each lane as shown in Fig. 5 are known to be due to alternative poly-A adenylations (Tone et al., 1992). This result suggests that A3 (CD59) can be a candidate molecule for mediating bone preferential homing of both breast cancer and prostate cancer.

Clone A5: The sequence of clone A5 (1.0 kb) is highly homologous to a previously cloned cDNA deposited in the GenBank; however, 5' end of A5 differs from this cDNA, and A5 lacks a 66 bp short sequence in the middle. We confirmed existence of A5 transcript by RT-PCR using specific primers, and hypothesize that A5 is a splicing variant of this known sequence. The results of Northern blot hybridization with a probe, which would recognize both A5 and the known sequence, in human cancer cell lines

and human breast cancer tissues are shown in Fig. 6. This probe was positive in all the cancer cell lines except a lung cancer cell line. Non-bone metastatic breast cancer cell lines (MDA-MB-361 and MCF7) are also positive. Expression in human breast cancer tissues is higher than in normal control tissues in at least in two of the four cases, although the RNA samples in this particular commercial blot show some degradation. We are currently raising rabbit antibodies against a putative peptide of A5 and that of the known cDNA.

In vivo experiment to test the ability of CD59-expressing or A3-expressing cells to home to bone marrow in vivo

We originally planned to visualize the homing of human CD59-expressing cells or A3-expressing cells by immunohistochemistry, since human CD59 and mouse CD59 are quite different (40 % homology in their DNA sequences, 11 % in their amino acid sequences), and endogenous mouse CD59 is unlikely to cross react to antibodies against human CD59. We tested four commercially available antibodies against human CD59, goat polyclonal to N-terminal peptide (Santa Cruz Bio, Santa Cruz, CA), goat polyclonal to C-terminal peptide (Santa Cruz Bio, Santa Cruz, CA), mouse monoclonal clone MEM-43 (Sanbio, Amuden, Netherlands), and mouse monoclonal clone 193-27 (NeoMakers, Fremont, CA). We found that none of these antibodies was suitable for immunohistochemistry on formalin fixed mouse tissue. Therefore we decided to use human placental alkaline phosphatase (PLAP) as a reporter protein to identify injected cells.




Fig.6 Northern blots with 600 bp A5 probe. Cell lines are as same as the blots with A3 probe. Northern blot shown in the right was a commercial filter containing ten μ g of total RNA from human breast cancer tissue and each normal control tissue.




Fig. 8: Alkaline phosphatase staining of the CD59+/PLAP+ clone CHO-B2b9 and the CD59-/PLAP+ control clone CHO-B2a12.

We have an affinity purified rabbit anti-PLAP antibody that works for immunohistochemistry on mouse tissue (Narisawa et al., 1993). Firstly, a transformant clone of Chinese Hamster Ovary (CHO) cells expressing human PLAP (Hummer et al., 1991) was transfected with CD59/pCMV-Script vector and G418 resistant clones were isolated. It was necessary to perform single cloning by limiting dilution, because all the 12 isolated G418+ clones tested contained high number of negative cells. We have selected two CHO cell clones (B2b9 and B2e3) as CD59+/PLAP+ cells and one clone (B2a12) as control cells (CD59-/PLAP+) (Fig. 8).




Fig. 9 describes the strategy to be followed to evaluate the specific homing of the transfectants to the bone marrow. The cells will be injected into left cardiac ventricle of Balb/c mouse, and after 1 hour of incubation, the injected mice will be analyzed. We are currently comparing a method with perfusion and exsanguination prior to sampling of the organs.

Fig. 9: Strategy to evaluate specific homing of transfected cells.

A novel *in vivo* expression cloning experiment

In our initial proposal we planed to isolate peptide motifs that home to bone marrow by *in vivo* organ targeting strategy. However, we found that small phage particles (1-2 μ m length in filamentous phage) were non-specifically captured by bone marrow cells due to phagocytic activity (most likely, by stromal cells, macrophages and/or endothelial cells). We have now rethought our *in vivo* targeting strategy to bypass those problems. We have used the mammalian expression COS-1 cell cloning system described above and applied it to develop a new *in vivo* expression cloning system as shown in Fig. 10. In this approach plasmids in COS-1 cells will be




Fig. 10: New *in vivo* targeting using COS-1 cells transfected with MDA-MB-231 cDNA expression library.

recovered from the bone marrow tissue of injected mice. We have obtained a total 20 plasmid clones (3 are the same clones) as shown in below (TABLE). We have chosen 15 clones (bold letters in the table) for individual analysis. COS-1 cells expressing each clone will be injected into mice together with COS-1 cells transfected with the pSVT7 plasmid, which carries an ampicillin resistance gene. The ratio of kanamycin resistant bacteria colonies, which contain the testing cDNA clones in pCMV-Script to the number of ampicillin resistant bacteria colonies, which contain pSVT7, will be compared between the DNA samples recovered from bone marrow and lung. Lung tissue traps COS-1 cells randomly and we use the lung sample as control. Any clone that gives higher ratio of kanamycin resistant colonies in bone marrow than lung, will be considered a candidate clone. We will make stable transforms of such clones and test bone homing as described above..

TABLE: List of new clones obtained by use of the modified *in vivo* targeting strategy.

clone	bac	size	Blast nr	Blast est	known prt?	predicted.prt	source	chr
26.1	XL10	2.7	AC008114 (BAC)	BE889643	no	?	leiomyosarcoma	12
26.3	XL10	1	AK001750			FLJ10888	terato ca	4
26.4	XL10		AF347002		mitochondrial DNA			mitc
11.1	XL-B	1.5	XM_002665.6	BF593640	Cys-rich protein		motor neuron, glioblastoma	4
11.2	XL-B				ribosomal protein S30		hypothalamus	11
11.4	XL10	1.8	XM_028947.1	BI463917		FLJ10468	testis	1
11.6	XL10	0.85*	XM_004593.1	BI115910	sorcin (ca binding prt)		lung small cell ca, MGC3	7
11.7	XL10		BC005002	BI834883	mitochondria ribosomal		lymphoma,pancr.spleen	5
11.8	XL10	0.35	AC092849.4	AI524014	no	ORF 155 aa	B-cell leukemia	7
11.9	XL10	1.3	BC014391	BI911460	no	ORF 219 aa	leukocyte, renal ad.ca	2
11.10	XL10	2.0**	XM_048403.1	BI011099	filamin A, actin binding prt		normal lung,	X
11.11	XL10	1.6	BC001357		no	SP260, FLJ10243	melanoma	
11.12	XL10	0.65	XM_001468		calpactin I(p11)ca-binding			1
11.13	XL10	0.28***	?		unknown			1
11.14	XL10	0.65	XM_001468		calpactin I(p11)ca-binding			
11.15	XL10	1.5	XM_002665.6		Cys-rich protein		motor neuron, glioblastoma	4
11.16	XL10	1.7	BC001590		man.6 P receptor binding prt		colon adeno ca	19
11.17	XL10		AB009010		ubiquitin C			
11.18	XL10	0.28***	?		unknown			12
11.19	XL10	1.4	NM003299.1		tumor rejection antigen(gp96)		terato ca LASTD	
11.20	XL10	0.6	XM_03470.1		DAD-1		Raji	

* 0.4+0.45

**1.4+0.6

***0.18+0.1

7. KEY RESEARCH ACCOMPLISHMENTS

- Characterization of bone marrow stromal and endothelial cell lines
- Development of two binding assays to be used in expression cloning by an *in vitro* panning procedure
- Cloning and initial characterization of two novel cDNAs mediating the binding of a metastatic breast cancer cell line to an immortalized bone marrow stromal cell line.
- Development of an *in vivo* screening procedure for organ-specific targeting
- Development of a novel *in vivo* targeting strategy to obviate the phagocytosis problem associated with the use of random peptide library *in vivo* targeting based on phage technology.

8. REPORTABLE OUTCOMES

A manuscript describing these novel panning and *in vivo* targeting strategies is in preparation.

9. CONCLUSIONS

We have requested and received approval to extend the duration of our approved grant until July 2002, without additional funds. This extra time will allow us to complete the studies and publish our conclusions. During this final year of support, we will complete the characterization of clone A3 and A5, which appear to be novel molecules. We will complete the evaluation of the specific targeting properties of these two molecules using the *in vivo* strategy outlined above. We will also initiate a thorough analysis of the additional 15 sequences that were identified by the new *in vivo* targeting strategy.

10. REFERENCES

Apaja-Sarkkinen M., Autio-Harmainen H., Alavaikko M., Risteli J., Risteli L. (1886) Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. British Journal of Haematology. 63(3), 571-580

Cailleau R. Young R. Olive M. Reeves WJ Jr. (1974) Breast tumor cell lines from pleural effusions Journal of the National Cancer Institute. 53(3), 661-674, 1974

Chen, S., Caragine, T., Cheung, N.K., Tomlinson, S. (2000) CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Research. 60(11), 3013-3018

Haq, M., Goltzman, D., Tremblay, G., Brodt, P. (1992) Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Research. 52, 4613-4619

Hummer, C., and Millán, J.L. Gly⁴²⁹ is the major determinant of uncompetitive inhibition of human germ cell alkaline phosphatase by L-Leucine. Biochem. J. 274: 91-95 (1991)

Hynes, R.O., Lander, A.D. (1992) Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell. 68, 303-322

Jacobsen, K., Kravitz, J., Kincade, P.W., Osmond, D.G. (1996) Adhesion receptors on bone marrow stromal cells: *in vivo* expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood. 87, 73-82

Jat P.S., Noble M.D., Ataliotis P., Tanaka Y., Yannoutsos N., Larsen L., Kioussis D. (1991) Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse Proceedings of the National Academy of Sciences of the United States of America. 88(12), 5096-5100

Lesley J., Hyman R., Kincade, P.W. (1993) CD44 and its interaction with extracellular matrix. Advances in Immunology. 54, 271-335

McMahon, R.F., McWilliam, L.J., Clarke, N.W., George N.J. (1994) Altered saccharide sequences in two groups of patients with metastatic prostatic carcinoma. British Journal of Urology. 74, 80-85

Michigami, T. Shimizu, N. Williams, P.J. Niewolna, M. Dallas, S.L. Mundy ,G.R. Yoneda, T. (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood. 96(5), 1953-1960

Narisawa, S., Smans, K., Avis, J., Hoylaerts, M. F. and Millán, J. L. Transgenic mice expressing the tumor marker germ cell alkaline phosphatase: An *in vivo* tumor model for human cancer antigens. Proc. Natl. Acad. Sci. USA 90: 5081-5085 (1993)

Tone, M. Walsh, L.A. Waldmann, H. (1992) Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. Journal of Molecular Biology. 227(3), 971-976

Yoneda, T. Sasaki, A. Mundy, G.R. (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Research & Treatment. 32(1), 73-84

Zetter, B.R. (1993) Adhesion molecules in tumor metastasis. Seminars in Cancer Biology. 4, 219-229